

## LEQEMBI (lecanemab) ORDER FORM P: 240.200.4464 F: 240.892.3005

PATIE	ENT INFO	ORMATION:	Fax comp	leted form, ii	nsurance inform	nation,	and clin	nical documentation to 240.892.3005		
Patient	Name:				DOB:			Phone:		
Patient	t Status:	□ New to <sup>-</sup>	Гherapy	Continu	uing Therapy		Next T	reatment Date:		
MED	ICAL INF	ORMATION	J .							
			_ lbs./kg	(required)	Allergies:					
Diagno			<b>F</b> . 1	0		_		· · · / D'· · · · · · · · · · · · · · · · · · ·		
			-	-	-			imer's Disease, unspecified (ICD-10	-	
		Alzheimer's D		-	.0: G30.1) 8\		wina	Cognitive Impairment (ICD-10: G31.	.84)	
				CD-10. 030.	8)					
THERAPY ORDER										
-			ery 2 we	eks for: (pl	ease select	-	4			
	st 5 dose	S					1 year			
□ 6 n	nonths						Other:			
<ul> <li>MRIs should be performed at baseline &amp; prior to the 5<sup>th</sup>, 7<sup>th</sup>, and 14<sup>th</sup> infusions</li> <li>HOLD INFUSION IF MRI IS NOT PERFORMED AT INDICATED INTERVAL</li> </ul>										
ADDITIONAL REQUIRED DOCUMENTATION FOR REFERRAL PROCESSING & INSURANCE APPROVAL										
	Patient enrolled in the CMS National Patient Registry (Medicare and Medicare Advantage required)									
	Issue number: Date of registry enrollment: Confirmed presence of amyloid pathology. Attach results: Amyloid PET scan OR +CSF (cerebrospinal fluid)									
<ul> <li>Cognitive assessment scores (list all available, attach results):</li> </ul>										
•	-				fassessment					
🗆 Fui	Functional assessment score: (attach results)									
🗆 Do	Does the patient have objective impairment in episodic memory as evidenced by a memory test (i.s., Fred ar									
Cu	ed, Wecl	nsler, etc.)? *	*BCBS re	quired** [	🗌 Yes 🗌 No					
🗆 Ist	he patie	nt on therap	eutic ant	icoagulant t	therapy? 🗌 🗎	/es 🗌	No			
PRO	/IDER IN	IFORMATIO	N							
Provider Name:			Signature:			Date:				
Provider NPI:			Phone:				Fax:			
Contac	t Person	:								